Fatima Zarzour, John T Schousboe, Neil Binkley, Didier Hans, William D Leslie
{"title":"质子泵抑制剂暴露,骨小梁评分和骨矿物质密度:一项基于登记的队列研究。","authors":"Fatima Zarzour, John T Schousboe, Neil Binkley, Didier Hans, William D Leslie","doi":"10.1093/jbmr/zjaf072","DOIUrl":null,"url":null,"abstract":"<p><p>Proton pump inhibitors (PPI) are widely-prescribed medications. PPI exposure may be associated with lower trabecular bone score (TBS), but has not shown a consistent effect on bone mineral density (BMD). We hypothesized that abdominal obesity, which is associated with both gastroesophageal disease and PPI use, could confound the relationship between PPI use and TBS. We assessed the effect of PPI use on TBS (primary measurement) and BMD (secondary measurements) before and after adjustment for sagittal abdominal diameter (SAD), a DXA-derived measure of abdominal soft-tissue thickness. The study population comprised 60 930 individuals (90.3% women, mean age 65.7 yr) that included 11 340 (18.6%) with PPI use in the preceding 12 mo. PPI exposure was categorized from medication persistence ratio (MPR) as non-use (referent), minimal (MPR 0.01-0.25), mild (MPR 0.26-0.5), moderate (MPR 0.51-0.75) and high use (MPR 0.76-1). When logistic regression models were minimally-adjusted for age, sex and scanner, increasing PPI use versus non-use was associated with progressively increasing odds ratios (ORs) for TBS in the lowest tertile (minimal 1.11 [95% CI 1.02-1.22], mild 1.18 [1.04-1.34], moderate 1.34 [1.17-1.53], high 1.41 [1.31-1.52]) but inversely with osteoporotic BMD (minimal 0.97 [0.89-1.06], mild 0.85 [0.75-0.97], moderate 0.82 [0.72-0.94]), high 0.76 [0.70-0.82]). SAD was greater in PPI users than non-users. After further adjustment for SAD, PPI use was not associated with lower TBS or BMD. Similar patterns were seen in men and women, and for longer durations of PPI use. Among 4742 with a second DXA (mean interval 3.4 yr), PPI use was not associated with more rapid TBS or BMD loss compared to non-users. In conclusion, PPI use is associated with greater SAD, an indicator of abdominal obesity. SAD and other clinical variables have a confounding effect on TBS and BMD measurements. When fully-adjusted, PPI exposure did not significantly decrease TBS or BMD.</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proton Pump Inhibitor Exposure, Trabecular Bone Score and Bone Mineral Density: A Registry-Based Cohort Study.\",\"authors\":\"Fatima Zarzour, John T Schousboe, Neil Binkley, Didier Hans, William D Leslie\",\"doi\":\"10.1093/jbmr/zjaf072\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Proton pump inhibitors (PPI) are widely-prescribed medications. PPI exposure may be associated with lower trabecular bone score (TBS), but has not shown a consistent effect on bone mineral density (BMD). We hypothesized that abdominal obesity, which is associated with both gastroesophageal disease and PPI use, could confound the relationship between PPI use and TBS. We assessed the effect of PPI use on TBS (primary measurement) and BMD (secondary measurements) before and after adjustment for sagittal abdominal diameter (SAD), a DXA-derived measure of abdominal soft-tissue thickness. The study population comprised 60 930 individuals (90.3% women, mean age 65.7 yr) that included 11 340 (18.6%) with PPI use in the preceding 12 mo. PPI exposure was categorized from medication persistence ratio (MPR) as non-use (referent), minimal (MPR 0.01-0.25), mild (MPR 0.26-0.5), moderate (MPR 0.51-0.75) and high use (MPR 0.76-1). When logistic regression models were minimally-adjusted for age, sex and scanner, increasing PPI use versus non-use was associated with progressively increasing odds ratios (ORs) for TBS in the lowest tertile (minimal 1.11 [95% CI 1.02-1.22], mild 1.18 [1.04-1.34], moderate 1.34 [1.17-1.53], high 1.41 [1.31-1.52]) but inversely with osteoporotic BMD (minimal 0.97 [0.89-1.06], mild 0.85 [0.75-0.97], moderate 0.82 [0.72-0.94]), high 0.76 [0.70-0.82]). SAD was greater in PPI users than non-users. After further adjustment for SAD, PPI use was not associated with lower TBS or BMD. Similar patterns were seen in men and women, and for longer durations of PPI use. Among 4742 with a second DXA (mean interval 3.4 yr), PPI use was not associated with more rapid TBS or BMD loss compared to non-users. In conclusion, PPI use is associated with greater SAD, an indicator of abdominal obesity. SAD and other clinical variables have a confounding effect on TBS and BMD measurements. When fully-adjusted, PPI exposure did not significantly decrease TBS or BMD.</p>\",\"PeriodicalId\":185,\"journal\":{\"name\":\"Journal of Bone and Mineral Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Bone and Mineral Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jbmr/zjaf072\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jbmr/zjaf072","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
质子泵抑制剂(PPI)是广泛使用的处方药。PPI暴露可能与较低的骨小梁评分(TBS)有关,但尚未显示出对骨矿物质密度(BMD)的一致影响。我们假设腹部肥胖与胃食管疾病和PPI使用相关,可能混淆PPI使用和TBS之间的关系。我们评估了在调整矢状腹直径(SAD)前后使用PPI对TBS(主要测量)和BMD(次要测量)的影响,矢状腹直径是dxa衍生的腹部软组织厚度测量。研究人群包括60 930人(90.3%为女性,平均年龄65.7岁),其中11 340人(18.6%)在过去12个月内使用过PPI。PPI暴露按药物持续比(MPR)分为不使用(参考)、最小(MPR 0.01-0.25)、轻度(MPR 0.26-0.5)、中度(MPR 0.51-0.75)和高使用(MPR 0.76-1)。当logistic回归模型对年龄、性别和扫描仪进行最小调整时,增加PPI使用与不使用与最低分位数TBS的比值比(or)逐渐增加相关(最小1.11 [95% CI 1.02-1.22],轻度1.18[1.04-1.34],中度1.34[1.17-1.53],高1.41[1.31-1.52]),但与骨质疏松症骨密度呈负相关(最小0.97[0.89-1.06],轻度0.85[0.75-0.97],中度0.82[0.72-0.94]),高0.76[0.70-0.82])。PPI使用者的SAD发生率高于非PPI使用者。在进一步调整SAD后,PPI的使用与较低的TBS或BMD无关。在男性和女性中发现了类似的模式,并且PPI使用时间更长。在4742例第二次DXA患者(平均间隔3.4年)中,与未使用PPI的患者相比,使用PPI与更快的TBS或BMD损失无关。总之,PPI的使用与SAD的增加有关,SAD是腹部肥胖的一个指标。SAD和其他临床变量对TBS和BMD测量有混淆作用。当完全调整后,PPI暴露并没有显著降低TBS或BMD。
Proton Pump Inhibitor Exposure, Trabecular Bone Score and Bone Mineral Density: A Registry-Based Cohort Study.
Proton pump inhibitors (PPI) are widely-prescribed medications. PPI exposure may be associated with lower trabecular bone score (TBS), but has not shown a consistent effect on bone mineral density (BMD). We hypothesized that abdominal obesity, which is associated with both gastroesophageal disease and PPI use, could confound the relationship between PPI use and TBS. We assessed the effect of PPI use on TBS (primary measurement) and BMD (secondary measurements) before and after adjustment for sagittal abdominal diameter (SAD), a DXA-derived measure of abdominal soft-tissue thickness. The study population comprised 60 930 individuals (90.3% women, mean age 65.7 yr) that included 11 340 (18.6%) with PPI use in the preceding 12 mo. PPI exposure was categorized from medication persistence ratio (MPR) as non-use (referent), minimal (MPR 0.01-0.25), mild (MPR 0.26-0.5), moderate (MPR 0.51-0.75) and high use (MPR 0.76-1). When logistic regression models were minimally-adjusted for age, sex and scanner, increasing PPI use versus non-use was associated with progressively increasing odds ratios (ORs) for TBS in the lowest tertile (minimal 1.11 [95% CI 1.02-1.22], mild 1.18 [1.04-1.34], moderate 1.34 [1.17-1.53], high 1.41 [1.31-1.52]) but inversely with osteoporotic BMD (minimal 0.97 [0.89-1.06], mild 0.85 [0.75-0.97], moderate 0.82 [0.72-0.94]), high 0.76 [0.70-0.82]). SAD was greater in PPI users than non-users. After further adjustment for SAD, PPI use was not associated with lower TBS or BMD. Similar patterns were seen in men and women, and for longer durations of PPI use. Among 4742 with a second DXA (mean interval 3.4 yr), PPI use was not associated with more rapid TBS or BMD loss compared to non-users. In conclusion, PPI use is associated with greater SAD, an indicator of abdominal obesity. SAD and other clinical variables have a confounding effect on TBS and BMD measurements. When fully-adjusted, PPI exposure did not significantly decrease TBS or BMD.
期刊介绍:
The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale “-omics” approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.